Drug Search Results
More Filters [+]

Oblimersen

Alternative Names: oblimersen, g3139
Latest Update: 2023-12-20
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: BCL2 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: European Medicines Agency

Approved Indications: None

Known Adverse Events: None

Company: Genta
Company Location: BERKELEY HEIGHTS NJ 07922
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oblimersen

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Lymphoid Leukemia|Melanoma|Acute Myeloid Leukemia

Phase 2: Prostate Cancer|Kidney Cancer|Head and Neck Cancer|Adenocarcinoma|Hepatocellular Carcinoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Bladder Cancer|Carcinoma, Merkel Cell|Leukemia, Plasma Cell|Intraocular Lymphoma|Ovarian Cancer|Colorectal Cancer|Lung Cancer|Breast Cancer|Mantle-Cell Lymphoma|Follicular Lymphoma|Esophageal Cancer|Waldenstrom Macroglobulinemia|Neuroendocrine Carcinoma|Chronic Lymphoid Leukemia|Extranodal NK-T-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Male Breast Cancer|Plasmablastic Lymphoma|Liver Cancer|Lymphomatoid Granulomatosis|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Cutaneous Lymphoma|Adult T-Cell Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Renal Cell Carcinoma|B-Cell Marginal Zone Lymphoma|Burkitt Lymphoma|Melanoma|Gastrointestinal Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Gastrointestinal Stromal Tumors|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia

Phase 1: Oncology Solid Tumor Unspecified|Lymphoma, Non-Hodgkin|T-Cell Cutaneous Lymphoma|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma|B-Cell Marginal Zone Lymphoma|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Adult T-Cell Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Plasmablastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Kidney Diseases|Melanoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01200342

P2

Terminated

Melanoma

2013-09-01

0462-07-FB

P1

Terminated

Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma

2012-10-09

AGENDA

P3

Completed

Melanoma

2011-05-01

2007-003340-30

P3

Completed

Melanoma

2011-04-28

Recent News Events